Opinion: To allocate remdesivir fairly, give it to communities that bear a disproportionate burden of Covid-19
As the federal government haphazardly distributed remdesivir, Gilead Sciences’ repurposed antiviral drug, to some of the states hit hardest by Covid-19, policymakers scrambled to develop criteria to allocate the drug to their hospitals.
Our state, Michigan, was among these states. The disparities in the burden of suffering from Covid-19 in the state are striking. Detroit’s death rate from the infection are more than four times the state average. So you might think that Detroit would have been high on the list for getting remdesivir.
